Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2012

View Archived Issues

Scientists prepare new agents for urological disorders

Novel ddRNAi agents developed for hepatitis B

New immunomodulating fusion proteins presented by MIVAC Development

Tumor-targeting nanoparticle therapy shows promise in phase I testing

Taiho to kick off global phase III study RECOURSE

Peripheral blood monocyte biomarkers linked to emphysema

Allergic rhinitis drug reduces nasal symptoms in clinical trial

Bayer Schering Pharma divulges novel anticancer agents

U.S. team patents new DAP kinase 1 inhibitors and PPAR-gamma/GPR120 partial agonists

RELAX study assesses Botox in women with OAB

Clearance given for first-in-human trial of RXI-109

Viamet Pharmaceuticals discloses novel metalloenzyme inhibitors

Enrollment complete in pivotal CRUISE-1 study

Researchers at ProMetic Life Sciences report novel phenylketone carboxylates

GSK files for approval of eltrombopag for new indications

Dynamic Pharmaceuticals discovers new activators of pyruvate kinase isozyme M2

Primary endpoint met in phase IIb study of Visonac

Multiple-ascending-dose trial evaluates ARRY-502 pharmacokinetics

Treatment begins in study of Genelux's vaccinia-based oncolytic viral therapy

Eisai files application in Japan for Pariet triple-formulation pack

Omeros launches substudy in phase III OMS-302 program

Tau Therapeutics and NCI begin clinical study of Interlaced Therapy

Chelsea Therapeutics reports on preliminary analysis of phase II trial in RA

Bayer Yakuhin launches new granule formulation of Fosrenol in Japan

Oncothyreon commences phase I/II trial of PX-866 with Zelboraf

Pivotal TOWER trial meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...